In silico molecular docking study of natural compounds on wild and mutated epidermal growth factor receptor

被引:51
|
作者
Singh, Pushpendra [1 ]
Bast, Felix [1 ]
机构
[1] Cent Univ Punjab, Ctr Biosci, Sch Basic & Appl Sci, Bathinda 151001, Punjab, India
关键词
Cancer; Epidermal growth factor receptor; Mutation; Natural compound; Maestro 9.3 (Schrodinger 2012); CELL LUNG-CANCER; PROSTATE-CANCER; KINASE INHIBITORS; TYROSINE KINASES; ANDROGEN RECEPTOR; ACCURATE DOCKING; DOWN-REGULATION; T790M MUTATION; EGFR T790M; GEFITINIB;
D O I
10.1007/s00044-014-1090-1
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The role played by overexpression of tyrosine kinase epidermal growth factor receptor (EGFR), the transmembrane receptor central to numerous cellular processes comprising cell migration, adhesion, apoptosis, and cell proliferation, has been highlighted in various cancers such as prostate, breast, lung, and ovarian cancers as well as in mutations in the EGFR kinase domain. Although many therapeutic approaches have targetted EGFR, the mutations occurring in the EGFR kinase domain including L858 EGFR and T790/L858R had led to the amplification of EGFR signals, consequently leading to increased cell proliferation and cell growth. The strategies involving the inhibition of EGFR L858 and T790M have been accredited with limited achievement in addition to being associated with unwanted adverse effects as a result of crosstalk of wild-type EGFR. All current EGFR tyrosine kinase inhibitors have been identified as ATP competitive inhibitors of wild-type EGFR possessing aniline and quinazoline moiety on the ligands skeleton. Our results obtained by performing molecular docking study on Maestro 9.3 molecular docking suite indicated that CID5280343 possesses better energy conformation against wild-type EGFR as well as two mutated EGFR. Moreover, it was discovered in this study that the natural compounds CID72276, CID5280445, CID441794, and CID72277 and InterBioScreen's library STOCK1N-78657, STOCK1N-78976, and STOCK1N-78847 have better binding conformation against gatekeeper T790M mutated EGFR concluded to be brought about by means of flexible ligands/receptor-based molecular docking protocol. Miraculous features of these compounds are their various pharmacokinetic and pharmacodynamic parameters which were found to be satisfactory as drug-like molecules. This molecular docking study also summarizes docking free energy, protein-ligands interaction profile, and pharmacokinetic and pharmacodynamic parameter of lead molecules which were tremendously helpful in enhancing the activity of these natural compounds against EGFR.
引用
收藏
页码:5074 / 5085
页数:12
相关论文
共 50 条
  • [21] In Silico Identification of Novel Erlotinib Analogues Against Epidermal Growth Factor Receptor
    Sheikh, Ishfaq A.
    Hassan, Hani Mutlak A.
    ANTICANCER RESEARCH, 2016, 36 (11) : 6125 - 6132
  • [22] Molecular Targeting of Epidermal Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR)
    Kaufman, Nichole E. M.
    Dhingra, Simran
    Jois, Seetharama D.
    Vicente, Maria da Graca H.
    MOLECULES, 2021, 26 (04):
  • [23] EXPRESSION OF MUTATED EPIDERMAL GROWTH-FACTOR RECEPTOR BY NONSMALL CELL LUNG CARCINOMAS
    DEPALAZZO, IEG
    ADAMS, GP
    SUNDARESHAN, P
    WONG, AJ
    TESTA, JR
    BIGNER, DD
    WEINER, LM
    CANCER RESEARCH, 1993, 53 (14) : 3217 - 3220
  • [24] Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non-Small-Cell Lung Cancer
    Laurie, Scott A.
    Goss, Glenwood D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (08) : 1061 - 1069
  • [25] Molecular Mechanisms that Regulate Epidermal Growth Factor Receptor Inactivation
    Ceresa, Brian P.
    Vanlandingham, Phillip A.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2008, 2 : 47 - 61
  • [26] Molecular imaging of epidermal growth factor receptor kinase activity
    Khan, Amjad P.
    Contessa, Joseph N.
    Nyati, Mukesh K.
    Ross, Brian D.
    Rehemtulla, Alnawaz
    ANALYTICAL BIOCHEMISTRY, 2011, 417 (01) : 57 - 64
  • [27] Molecular Probes for Targeting and Imaging of the Epidermal Growth Factor Receptor
    Hung, C.
    Kuo, Y.
    Baulch, J. E.
    Raghavan, S.
    Gullapali, R.
    Suntharalingam, M.
    D'Souza, W. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S163 - S163
  • [28] Molecular basis for multimerization in the activation of the epidermal growth factor receptor
    Huang, Yongjian
    Bharill, Shashank
    Karandur, Deepti
    Peterson, Sean M.
    Marita, Morgan
    Shi, Xiaojun
    Kaliszewski, Megan J.
    Smith, Adam W.
    Isacoff, Ehud Y.
    Kuriyan, John
    ELIFE, 2016, 5
  • [29] Kinetic and thermodynamic insights into interaction of erlotinib with epidermal growth factor receptor: Surface plasmon resonance and molecular docking approaches
    Mohammadzadeh-Asl, Saeideh
    Aghanejad, Ayuob
    Yekta, Reza
    de la Guardia, Miguel
    Dolatabadi, Jafar Ezzati Nazhad
    Keshtkar, Ahmad
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2020, 163 : 954 - 958
  • [30] Design of New Quinazoline Derivative as EGFR (Epidermal Growth Factor Receptor) Inhibitor through Molecular Docking and Dynamics Simulation
    Rasyid, Herlina
    Purwono, Bambang
    Pranowo, Harno Dwi
    INDONESIAN JOURNAL OF CHEMISTRY, 2021, 21 (01) : 201 - 211